Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $2 to $4.